Answers are grounded in this paper and cite their sources.
While clinical management of oral squamous cell carcinoma (OSCC) has seen substantial progress, its incidence and mortality rates have shown minimal improvement over the past three decades. Recent studies highlight the therapeutic potential of solute carrier organic anion transporter family member 1B3 (SLCO1B3) in head and neck squamous cell carcinoma, yet its precise mechanistic role in OSCC remains elusive. Through pan-cancer expression profiling, we identified marked heterogeneity in SLCO1B3 expression across tumor types, with marked upregulation specifically observed in OSCC tissues. Systematic analysis of clinical datasets revealed a significant inverse correlation between SLCO1B3 expression levels and critical prognostic indicators, including overall patient survival. Functional enrichment analysis further demonstrated SLCO1B3's robust association with immune infiltration signatures, suggesting its involvement in shaping the tumor immune microenvironment. By integrating ESTIMATE microenvironment scoring and single-sample gene set enrichment analysis (ssGSEA), we uncovered SLCO1B3-mediated suppression of B-cell populations—particularly naive B cells—revealing a novel mechanism of immune evasion. These findings not only establish SLCO1B3 as a prognostic biomarker for OSCC but also provide mechanistic insights for developing immune microenvironment-targeted therapies.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: